Healthcare
Delcath Systems Inc.(DCTH)
Live Price
Offline$11.69
-2.01% today
Window Change
+6.77%
Window
May 29, 2026 โ Jun 22, 2026
- Market Cap
- $400.00M
- Revenue Growth
- +129.1%
- EPS Growth
- +108.1%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars ยท May 29, 2026 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Delcath Systems Inc. (DCTH) is a Healthcare stock with a market cap of $400.00M and listed on NASDAQ. The stock last traded around $11.69 and up 6.8% across the available one-year price window (May 29, 2026 โ Jun 22, 2026). Baseline metrics include revenue growth of +129.1%, EPS growth of +108.1%, a dividend yield of 0.0%. What stands out right now is revenue +129.1%, EPS +108.1%, free cash flow +209.0% with operating margin 0.8% and ROIC 0.5%. Valuation already assumes a fairly strong business story at P/E 155.6 and price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines DCTH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+129.1% vs +7.6% peer median
Operating Margin
Below sector median
+0.8% vs +19.4% peer median
P/E
Above sector median
155.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +129.1% and EPS at +108.1%, with operating margin around 0.8%.
Benchmark Edge
DCTH vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DCTH
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DCTH Max Drawdown
-4.28%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DCTH and SPY.
Company Overview
Delcath Systems Inc.
NASDAQ
Delcath Systems Inc. is a medical device company focused on providing treatment options for primary and metastatic liver cancers through its innovative technologies. Central to their product offerings is the percutaneous hepatic perfusion (PHP) system, which enables targeted delivery of high-dose chemotherapy directly to the liver. This approach aims to maximize impact on cancer cells while minimizing systemic exposure and related side effects. Delcath Systems Inc. operates primarily within the healthcare sector, impacting the medical device and oncology industries. The company engages with hospitals, medical professionals, and patients, contributing to evolving treatment protocols for liver cancer. By developing interventional medical solutions, Delcath Systems Inc. plays a significant role in advancing targeted cancer therapies and enhancing the arsenal of available tools in oncology. Headquartered in New York, the company is part of a growing movement towards personalized and precision medicine, seeking to improve patient outcomes through targeted therapeutic interventions.
- Leadership
- Mr. Gerard J. Michel MBA, MS
- Employees
- 96
- Street Address
- 566 Queensbury Avenue, 22nd Floor Suite C
- Mailing
- New York, NY, 12804
- Region
- New York, NY, United States
- Last Updated
- May 20, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 155.6
- EV/EBITDA
- 139.4
- Price/Sales
- 4.7
- Price/Book
- 3.8
Growth
- Revenue
- +129.1%
- EPS
- +108.1%
- Free Cash Flow
- +209.0%
Profitability
- Gross Margin
- 86.2%
- Operating Margin
- 0.8%
- Net Margin
- 3.2%
- ROE
- 2.6%
- ROIC
- 0.5%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 10.92
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.